David Lebowitz
Stock Analyst at Citigroup
(2.43)
# 2,385
Out of 4,734 analysts
98
Total ratings
47.89%
Success rate
-0.58%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Sell | $26 → $32 | $45.25 | -29.28% | 3 | Dec 4, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $47.98 | +41.73% | 4 | Nov 13, 2024 | |
| INCY Incyte | Maintains: Buy | $92 → $97 | $73.47 | +32.03% | 4 | Oct 30, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $25 → $19 | $9.94 | +91.15% | 6 | Oct 25, 2024 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $70 | $24.61 | +184.44% | 1 | Oct 7, 2024 | |
| COGT Cogent Biosciences | Maintains: Buy | $13 → $15 | $8.20 | +82.93% | 3 | Sep 24, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $178 → $207 | $131.06 | +57.94% | 12 | Sep 17, 2024 | |
| PLRX Pliant Therapeutics | Maintains: Buy | $45 → $44 | $11.07 | +297.47% | 4 | May 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Sell | $65 → $76 | $111.96 | -32.12% | 5 | May 3, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $39 → $37 | $21.33 | +73.46% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $307.08 | +24.40% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $46 | $36.08 | +27.49% | 2 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $36.43 | -14.91% | 1 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 → $60 | $32.68 | +83.60% | 11 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $62.53 | +53.53% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $2.12 | +466.04% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $264.99 | -38.11% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $13.08 | +198.17% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $13.67 | +53.62% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $27 | $0.69 | +3,830.70% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.79 | +269.39% | 2 | Oct 12, 2021 |
PTC Therapeutics
Dec 4, 2024
Maintains: Sell
Price Target: $26 → $32
Current: $45.25
Upside: -29.28%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $47.98
Upside: +41.73%
Incyte
Oct 30, 2024
Maintains: Buy
Price Target: $92 → $97
Current: $73.47
Upside: +32.03%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $25 → $19
Current: $9.94
Upside: +91.15%
Celldex Therapeutics
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $24.61
Upside: +184.44%
Cogent Biosciences
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $8.20
Upside: +82.93%
Ascendis Pharma
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $131.06
Upside: +57.94%
Pliant Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $45 → $44
Current: $11.07
Upside: +297.47%
Blueprint Medicines
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $111.96
Upside: -32.12%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $21.33
Upside: +73.46%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $307.08
Upside: +24.40%
Feb 23, 2024
Maintains: Buy
Price Target: $42 → $46
Current: $36.08
Upside: +27.49%
Dec 15, 2023
Initiates: Buy
Price Target: $31
Current: $36.43
Upside: -14.91%
Jul 31, 2023
Upgrades: Buy
Price Target: $36 → $60
Current: $32.68
Upside: +83.60%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $62.53
Upside: +53.53%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $2.12
Upside: +466.04%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $264.99
Upside: -38.11%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $13.08
Upside: +198.17%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $13.67
Upside: +53.62%
Oct 12, 2021
Maintains: Overweight
Price Target: $29 → $27
Current: $0.69
Upside: +3,830.70%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.79
Upside: +269.39%